Genome Publications
https://doi.org/10.61096/ 978-81-981372-8-9_8

Chapter 8

Persistent Alcohol Use And Herbal Hepatoprotectants

Murugeswari Krishnan
Department of Pharmacognosy, K. M. College of Pharmacy, Madurai, Tamilnadu, India.
Delphina Tenneyson
Department of Pharmacology, United College of Pharmacy, Coimbatore, Tamilnadu, India.
Dr. Prema Rathinam
Department of Pharmaceutics, Sir Issac Newton College of Pharmacy,
Coimbatore, Tamilnadu, India.
Dr. Sriram Nagarajan
Professor and Principal, Usha College of Pharmacy, Dhadkidih, Jharkhand, India.

Abstract: Excessive and persistent alcohol consumption is a leading cause of liver disease worldwide, contributing to conditions such as alcoholic fatty liver, alcoholic hepatitis, cirrhosis, and hepatocellular carcinoma. Alcohol metabolism generates toxic intermediates such as acetaldehyde, leading to oxidative stress, mitochondrial dysfunction, inflammation, and fibrosis. While pharmacological treatments like corticosteroids and pentoxifylline offer some benefits, they have limitations in efficacy and long-term safety. Herbal hepatoprotectants have emerged as potential complementary therapies, demonstrating antioxidant, anti-inflammatory, and anti-fibrotic effects that mitigate alcohol-induced liver damage. Botanicals such as Milk Thistle (Silymarin), Phyllanthus species, Curcumin, Licorice, and Schisandra have shown promise in reducing oxidative damage, modulating cytokine expression, and improving liver regeneration. Additionally, recent advancements in nanotechnology and omics-based research have enhanced the bioavailability and therapeutic potential of these phytochemicals. However, challenges related to standardization, regulatory oversight, herb-drug interactions, and the need for large-scale clinical trials remain critical barriers to their widespread adoption. This chapter explores the pathophysiology of alcohol-induced liver injury, the scientific mechanisms of hepatoprotective herbs, clinical evidence supporting their efficacy, and future directions for integrating these botanicals into mainstream liver disease management.

Keywords: Alcoholic liver disease, hepatoprotectants, oxidative stress, inflammation, fibrosis, Silymarin, Curcumin, Phyllanthus, Schisandra, herbal medicine, liver regeneration, complementary therapy, nanotechnology.

Citation: Murugeswari Krishnan, Delphina Tenneyson, Prema Rathinam, Sriram Nagarajan. Persistent Alcohol Use And Herbal Hepatoprotectants. *Advancements in Hepatoprotective Herbal Medicines Current Trends, Significance, and Future Perspectives.* Genome Publications. 2025; Pp97-106. https://doi.org/10.61096/978-81-981372-8-9_8

INTRODUCTION

Persistent alcohol use remains a critical determinant of public health, with harmful alcohol consumption contributing substantially to the global burden of disease and injury[1]. Individuals who engage in excessive drinking are at risk for a spectrum of hepatic disorders, including alcoholic fatty liver, alcoholic hepatitis, cirrhosis, and hepatocellular carcinoma[2]. The development of these conditions is driven by interconnected biochemical pathways, encompassing oxidative stress, inflammation, mitochondrial dysfunction, and disruptions in lipid metabolism[3]. While pharmacotherapies such as corticosteroids and pentoxifylline can mitigate some aspects of the disease, they often exhibit suboptimal long-term efficacy and may carry adverse effects[4]. This reality spurs ongoing research into alternative and complementary interventions that potentially offer broader therapeutic windows and fewer complications.

Herbal hepatoprotectants have gained traction as part of integrative medicine approaches, especially given their historical foundation in traditional systems like Ayurveda, Traditional Chinese Medicine, and Unani[5]. Modern scientific investigations highlight their antioxidant, anti-inflammatory, anti-fibrotic, and immunomodulatory properties, all of which are pertinent to countering alcohol-induced liver injury[6]. Beyond symptomatic relief, certain plant-derived compounds may stabilize hepatic architecture, regulate lipid pathways, and bolster the gut–liver axis, thereby offering multifaceted support to the diseased liver[7].

Despite these encouraging findings, concerns about variable extract quality, limited large-scale clinical trials, and inconsistent regulatory standards persist[8]. Researchers also note the possibility of herb – drug interactions, which can pose risks when combining botanical supplements with pharmaceutical agents[9]. Nevertheless, significant advancements in technologies such as nanodelivery systems and omics-based personalization suggest that these barriers can be systematically addressed[10].

This chapter delves into the pathophysiology of alcohol-induced liver damage, the mechanistic basis of herbal interventions, and the emerging scientific consensus regarding their clinical benefits. It further examines how these botanical agents fit into a broader therapeutic landscape that includes nutrition, lifestyle modifications, and conventional pharmacological regimens. By analyzing the challenges and future perspectives, the discussion aims to articulate a framework for integrating herbal hepato protectants into mainstream care for individuals with chronic alcohol use disorders.

Alcohol Metabolism and Pathophysiology

Chronic alcohol consumption activates a cascade of metabolic processes in the liver that collectively underlie alcoholic liver disease. Primary among these is the enzymatic conversion of ethanol to acetaldehyde via alcohol dehydrogenase and the cytochrome P450 2E1 system[11]. Acetaldehyde is a highly reactive compound that forms adducts with proteins, lipids, and DNA, compromising cellular integrity and invoking immunological responses[12]. Although aldehyde dehydrogenase can further oxidize acetaldehyde to acetate, genetic polymorphisms in these enzymes alter an individual's susceptibility to alcohol-induced liver damage[13].

Over time, the liver's antioxidant defenses, including glutathione and enzymes such as superoxide dismutase, become overwhelmed by reactive oxygen species generated through ethanol metabolism[14]. These reactive species induce lipid peroxidation, protein oxidation, and DNA fragmentation, collectively driving oxidative stress[15]. Concurrently, mitochondrial dysfunction arises, impairing ATP production and amplifying the production of reactive oxygen species[16].

The inflammatory component of alcoholic liver disease involves Kupffer cells, the liver's resident macrophages, which detect tissue injury and secrete cytokines like tumor necrosis factor-alpha and

interleukins[17]. This immune response triggers further damage by recruiting additional inflammatory cells. Activated hepatic stellate cells deposit collagen and other extracellular matrix proteins, leading to fibrosis and eventual cirrhosis if the injurious stimulus persists[18].

Nutritional deficiencies exacerbate these pathologies, as chronic alcoholism often correlates with inadequate intake of vitamins, minerals, and proteins essential for antioxidant defense and tissue repair[19]. Additionally, alcohol disrupts gut barrier integrity, allowing bacterial endotoxins to enter the portal circulation, which further intensifies hepatic inflammation and injury[20]. This interconnected network of oxidative stress, inflammation, fibrogenesis, and metabolic disruption underscores the complexity of alcoholic liver disease[21]. A deeper understanding of these pathways paves the way for exploring herbal hepatoprotectants that address multiple pathogenic mechanisms simultaneously.

HERBAL HEPATOPROTECTANTS: HISTORICAL AND SCIENTIFIC PERSPECTIVES

Traditional medicine systems have long championed the use of botanicals for liver health. Texts in Ayurveda detail numerous plants reputed to balance hepatic function, while Traditional Chinese Medicine prescribes formulations targeting “liver heat” or “qi stagnation”[22]. Over centuries, these practices accumulated empirical knowledge about plants that seemingly mitigated jaundice, abdominal discomfort, and other signs of hepatic stress.

Modern research validates many of these observations. A growing body of in vitro and in vivo studies demonstrates that phytochemicals in these plants reduce lipid peroxidation, modulate cytokine networks, and even encourage liver regeneration[23]. For instance, flavonoids extracted from certain herbs exhibit free radical scavenging capabilities that rival synthetic antioxidants[24]. Saponins may reduce inflammatory cell infiltration, while terpenoids can stabilize mitochondrial function[25].

Multiple factors contribute to the clinical impact of these herbal preparations. First, the synergy among diverse bioactive constituents can amplify therapeutic outcomes, allowing a single extract to exert antioxidative, anti-inflammatory, and anti-fibrotic activities in parallel[26]. Second, the relative safety profile of many herbal products, when used appropriately, contrasts with the more pronounced adverse effects of some pharmaceutical agents[27]. Third, advanced extraction methods help maintain the stability of these phytochemicals, increasing the likelihood of consistent batch-to-batch potency[28].

Nonetheless, significant hurdles remain in translating traditional practices into standardized, evidence-based treatments. Variability in plant species, geographic sourcing, and processing can yield inconsistent formulations. Regulatory authorities often classify these products as dietary supplements rather than drugs, meaning they undergo less stringent scrutiny[29]. Furthermore, large-scale randomized controlled trials, while increasingly common, are still not as prevalent for herbal interventions as for conventional medications[30]. Despite these challenges, the convergence of traditional wisdom and modern scientific methodology is driving a reevaluation of the role botanicals could play in managing alcohol-induced liver damage. Researchers continue to isolate, characterize, and test novel phytochemicals, while clinicians explore integrative care models that incorporate these agents into comprehensive treatment plans. Such efforts underscore that herbal hepatoprotectants, far from being mere folk remedies, represent a sophisticated and evolving dimension of liver therapeutics[31].

MECHANISMS OF ACTION OF HERBAL HEPATOPROTECTANTS

The multifactorial nature of alcohol-induced liver damage calls for interventions that operate at several biological levels. Herbal hepatoprotectants often fit this requirement by providing antioxidant, anti-inflammatory, anti-fibrotic, and immunomodulatory effects simultaneously. An essential mechanism is the neutralization of reactive oxygen species, a core driver of tissue injury in chronic alcohol exposure. Flavonoids and other polyphenols commonly found in hepatoprotective herbs can directly scavenge free radicals, while also upregulating endogenous antioxidants like glutathione[32]. Such modulation of redox balance mitigates cellular damage and sets the stage for tissue repair. Anti-inflammatory actions are equally significant. By inhibiting the nuclear factor-kappa B (NF-κB) pathway, certain herbal compounds reduce the production of pro-inflammatory cytokines that perpetuate liver injury[33]. Moreover, modulation of Kupffer cell activity limits the release of tumor necrosis factor-alpha and interleukins, which orchestrate inflammatory cascades in the liver.Fibrosis prevention and reversal involve interrupting hepatic stellate cell activation. Phytochemicals that interfere with transforming growth factor-beta signaling can reduce collagen deposition, slowing or even reversing fibrotic changes[34]. Some herbal extracts also enhance the activity of matrix metalloproteinases, which degrade excess extracellular matrix components[35].

Beyond these direct hepatic effects, herbal agents may influence upstream factors such as gut health. By improving intestinal barrier integrity and altering gut microbiota, certain botanicals reduce the influx of endotoxins that perpetuate hepatic inflammation[36]. Additionally, immunomodulatory properties help restore immune homeostasis, reducing the likelihood of an overzealous inflammatory response[37]. These mechanisms frequently intersect, reflecting the complexity of herbal pharmacology. While synthetic drugs often target one specific pathway, multi-component herbal extracts can hit multiple targets at once. This holistic coverage may account for their effectiveness in early to moderate stages of alcohol-related liver disease, although advanced cases still require intensive medical and possible surgical interventions[38].

NUTRITIONAL AND LIFESTYLE INTERVENTIONS

Nutrition and lifestyle modifications are integral to combating alcohol-induced liver disease, working synergistically with both conventional medications and herbal hepatoprotectants. The cornerstone intervention is abstinence, or at least substantial reduction, of alcohol intake. This step alone can halt ongoing damage and, in earlier stages, allow the liver to recover lost function. Achieving abstinence frequently requires psychological support, counseling, and sometimes pharmacological aids. Dietary optimization focuses on replenishing micronutrient deficits commonly observed in chronic alcoholism. Antioxidant vitamins (A, C, E) and minerals such as selenium and zinc can bolster hepatic defenses against oxidative stress. Adequate protein intake supports hepatocyte regeneration, while omega-3 fatty acids have shown promise in reducing liver inflammation and steatosis[39]. In contrast, diets high in saturated fats, simple sugars, and trans fatty acids may exacerbate lipid dysregulation, intensifying hepatic fat accumulation[40].

Physical activity complements dietary measures by improving insulin sensitivity, reducing visceral adiposity, and enhancing overall metabolic fitness[41]. Even moderate exercise has been linked to lower liver enzyme levels in individuals with steatosis. Stress management through mindfulness or cognitive-behavioral therapy can further stabilize hormonal and immunological fluctuations, indirectly benefiting hepatic health[42]. Many clinicians advocate a multi-tiered approach in which nutritional counseling, physical therapy, and psychological support converge to form a cohesive program. When patients adhere to these guidelines, the efficacy of herbal hepatoprotectants or conventional

medications can be significantly amplified. Conversely, the absence of complementary lifestyle changes may limit the benefits of any pharmacological or botanical agent.

CLINICAL EVIDENCE AND TRIALS

Clinical trials investigating herbal hepatoprotectants in alcohol-induced liver damage have yielded mixed but generally encouraging findings[43]. Early studies often relied on nonspecific end points like reductions in serum transaminases (AST, ALT) or bilirubin levels. Such improvements, while indicative of hepatocellular protection, lack the granularity to explain the full therapeutic impact of these botanicals[44].

Recent trials incorporate sophisticated biomarkers, including inflammatory cytokines, oxidative stress markers, and fibrotic indicators like collagen deposition or liver stiffness measured by elastography[45]. In these evaluations, certain herbal formulations demonstrated significant capacity to lower pro-inflammatory cytokines, enhance antioxidant enzyme activity, and mitigate fibrotic changes. Meta-analyses of randomized controlled trials on specific herbs, such as silymarin, have reported reduced mortality rates or slower progression to advanced disease stages[46].

However, the literature also highlights limitations, including small sample sizes, short study durations, and heterogeneity in herbal extract quality[47]. While some formulations are standardized to contain well-defined phytochemical concentrations, others rely on crude plant preparations, making cross-study comparisons difficult. Furthermore, trial designs seldom extend beyond one year, rendering data on long-term efficacy and safety relatively sparse[48]. Safety profiles, on the other hand, appear favorable in most documented cases, with mild gastrointestinal disturbances being among the most common side effects[49]. Nonetheless, clinicians caution that contamination or adulteration can occur in poorly regulated markets, and herb–drug interactions remain a concern for patients already on multiple medications. The collective evidence suggests that, when appropriately sourced and administered, herbal hepatoprotectants can play a valuable adjunctive role in managing alcoholic liver disease[50]. Ongoing and future large-scale trials that adhere to rigorous methodological standards will be pivotal in consolidating these findings into widely accepted clinical guidelines.

EMERGING TECHNOLOGIES IN HERBAL HEPATOPROTECTION

Technological advancements are reshaping how herbal hepatoprotectants are formulated, delivered, and validated. Nanotechnology has emerged as a potent tool for enhancing the bioavailability of phytochemicals that are otherwise poorly soluble in aqueous environments. Nano-encapsulation methods such as liposomes, solid lipid nanoparticles, and polymeric micelles protect these compounds from degradation, enable controlled release, and may even allow targeted delivery to hepatic cells[51]. Controlled-release systems and advanced extraction techniques further optimize the therapeutic potential of herbal extracts. Supercritical fluid extraction and microwave-assisted protocols can preserve thermolabile compounds and yield standardized extracts with minimal solvent residues. Once extracted, hydrogels or microsphere carriers can gradually release the phytochemicals, maintaining stable plasma concentrations and reducing dosing frequency[52]. Omics-based technologies offer additional insights by unraveling the complex molecular interactions between herbal compounds and liver cells. Genomic, proteomic, and metabolomic studies shed light on the pathways modulated by various phytochemicals, guiding personalized treatments based on individual genetic or metabolic profiles[53]. Artificial intelligence and machine learning algorithms can expedite the discovery of novel hepatoprotective agents by sifting through large phytochemical databases to identify potential synergies or interactions[54]. Blockchain systems also present a novel solution to traceability and authenticity concerns in herbal supply chains. By documenting every step from

cultivation to distribution, stakeholders can confirm product purity, reducing the likelihood of adulteration[55]. While these emerging technologies enhance efficacy, safety, and acceptance, their integration into routine clinical practice will hinge on cost-effectiveness, regulatory adaptation, and professional education[56].

CHALLENGES AND LIMITATIONS

The incorporation of herbal hepatoprotectants into mainstream alcohol-related liver disease management faces persistent challenges. A major issue is the lack of standardization in raw materials and final formulations. Variations in plant genetics, soil conditions, and harvesting methods can yield fluctuating levels of bioactive constituents, hindering reproducible clinical results. Regulatory classifications further complicate matters. In many jurisdictions, herbal products are regulated under dietary supplement laws that demand fewer safety and efficacy evaluations than pharmaceutical drugs. This regulatory gap can allow substandard or contaminated products to reach consumers, undermining confidence in the overall category of herbal therapies. Clinical evidence, although growing, remains somewhat uneven. Many studies are limited by small sample sizes, inadequate controls, or short durations, making it difficult to draw definitive conclusions about long-term benefits or potential adverse events. Additionally, discrepancies in dosing regimens, product formulations, and patient demographics hamper efforts to perform meta-analyses that can drive clinical guidelines.

Safety, while generally favorable, is not assured. Cases of adulteration with heavy metals or synthetic compounds have been reported in poorly regulated markets. Herb – drug interactions also pose significant risks, particularly for patients on multiple medications for comorbid conditions. Phytochemicals can inhibit or induce cytochrome P450 enzymes, altering drug metabolism in unpredictable ways[57]. From a socioeconomic perspective, cost and accessibility may impede widespread adoption of advanced formulations like nano-encapsulated herbs, especially in low-income regions. Public perception can also be a barrier, with some individuals mistakenly equating “natural” with “safe,” leading to unsupervised self-medication without professional guidance. Addressing these challenges requires a coordinated effort among researchers, clinicians, regulators, and the herbal industry. Enhanced standardization, robust clinical trial designs, strong pharmacovigilance programs, and clear regulatory pathways can collectively raise the credibility of herbal hepatoprotectants as legitimate contenders in the fight against alcohol-related liver damage.

POTENTIAL INTEGRATION STRATEGIES

Strategies for integrating herbal hepatoprotectants into alcohol-related liver disease management hinge on synergistic use with conventional therapies, rigorous scientific validation, and interdisciplinary collaboration. A practical approach starts with the development of standardized botanical extracts subjected to well-structured clinical trials. These trials can elucidate the most effective dosing regimens and the patient populations most likely to benefit. Combination therapy is another promising avenue. Pairing a potent anti-inflammatory herb with a conventional medication that targets fibrogenesis could broaden the therapeutic scope, potentially lowering the required doses of each agent and thus reducing side effects[58]. Interdisciplinary teams encompassing hepatologists, pharmacists, botanists, and nutritionists can design integrative protocols that also include lifestyle interventions for maximum efficacy[59]. Education stands out as a pivotal factor in successful integration. Clinicians trained in both conventional and traditional medicine paradigms can more effectively guide patients, making informed decisions about when to initiate, adjust, or discontinue herbal supplements[60]. Comprehensive guidelines published by professional societies can provide

structured recommendations, clarifying which herbs demonstrate sufficient evidence and how to mitigate risks like herb – drug interactions.

Regulatory collaboration remains essential. Harmonizing quality standards at national and international levels will instill confidence in manufacturers, clinicians, and patients alike. Such alignment can facilitate market entry for high-quality, proven products, helping them reach a broader demographic without compromising safety . Patient engagement is equally crucial. Transparent discussions about the realistic benefits and limitations of herbal hepatoprotectants can foster better adherence and help avoid misuse. Digital health tools that track liver function tests, symptom progression, and supplement usage can inform both patients and providers, offering real-time insights that refine individualized treatment strategies. Over time, these concerted efforts can promote a balanced view in which herbal hepatoprotectants are neither dismissed as unscientific nor embraced uncritically. Instead, they can be viewed as valuable components of a multifaceted approach tailored to the complex challenges posed by alcohol-induced liver disease.

FUTURE PERSPECTIVES

Alcohol-induced liver disease is poised to remain a global concern, reinforcing the need for innovative, multifaceted solutions. Herbal hepatoprotectants are well-suited for this role, especially as personalized medicine frameworks become more refined. Genomic and metabolomic analyses could identify patient subgroups most likely to respond favorably to specific phytochemicals, enabling physicians to create tailored regimens. Technological leaps in nanoformulation, controlled-release delivery, and machine learning will further optimize the safety and efficacy of herbal interventions. Targeted delivery systems can localize the active compounds to hepatic cells, minimizing systemic side effects and potentially enhancing therapeutic outcomes. Machine learning models, in particular, are expected to accelerate the discovery of new bioactive molecules from underexplored plant species, broadening the pharmacopeia for alcohol-related liver disease. Public health policies may also evolve to incorporate validated herbal hepatoprotectants within national guidelines for alcohol harm reduction. This integration could be especially impactful in resource-limited settings where advanced pharmaceuticals are scarce, and local herbal knowledge is abundant[61]. Collaborations between global health organizations, scientific institutions, and local communities can drive culturally sensitive interventions that respect indigenous practices while meeting contemporary standards of evidence and safety.

Sustainability will shape the future availability and credibility of these interventions. Overharvesting of medicinal plants and environmental degradation pose risks to the supply chain, prompting an increase in controlled cultivation, tissue culture, and even synthetic biology approaches to produce key phytochemicals[62]. Blockchain-based traceability systems may become more prevalent, reassuring stakeholders about the authenticity and quality of herbal products.

Ultimately, these advances point to a future where herbal hepatoprotectants are carefully integrated into the broader arsenal against alcohol-related liver disease. Their success will hinge on bridging traditional and modern knowledge systems, aligning regulatory frameworks, and maintaining rigorous scientific inquiry. The collective efforts of researchers, clinicians, policymakers, and patient communities will determine how effectively these botanical agents can fulfill their promise in ameliorating alcohol's toll on liver health.

CONCLUSION

Persistent alcohol use remains a formidable challenge, substantially impacting global health by driving oxidative stress, chronic inflammation, mitochondrial damage, and progressive fibrosis in the

liver. Standard medical therapies and harm-reduction tactics offer essential support but can fall short in addressing the intricate, multi-pathway nature of alcoholic liver disease. Against this backdrop, herbal hepatoprotectants emerge as a complementary strategy with a rich historical basis and a growing reservoir of modern scientific validation. Research spanning in vitro assays, animal models, and human trials points to the antioxidant, anti-inflammatory, and anti-fibrotic actions of botanical compounds. Though many hurdles persist such as product standardization, regulatory ambiguity, and the scarcity of large-scale clinical trials technological innovations in nanodelivery, omics-based personalization, and advanced extraction are steadily refining the precision and reliability of these interventions. The path forward involves converging efforts from multiple sectors: scientific research must deepen our understanding of botanical mechanisms and interactions; regulatory frameworks must evolve to ensure quality and safety; and clinicians must become adept at identifying which patients can benefit most from such integrative approaches. Patients, for their part, need clear, evidence-based guidance on safe and effective usage. By acknowledging both the limitations and the promise of herbal hepatoprotectants, healthcare systems can move toward more comprehensive models of care for individuals suffering from alcohol-induced liver damage. This integrative paradigm merging decades of clinical innovations with centuries of botanical wisdom offers a robust, patient-centered approach that may ultimately reduce the incidence and severity of alcoholic liver disease worldwide.

REFERENCES

1. World Health Organization. Global status report on alcohol and health. World Health Organization; 2018.
2. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011; 141(5): 1572 - 1585.
3. Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol. 2012; 56: S39 - S45.
4. Girish C, Pradhan SC. Herbal drugs on the liver with special emphasis on Indian herbs. J Clin Exp Hepatol. 2012; 2(2): 144 - 163.
5. Mandal P, Misra TK. Free radical scavenging and antioxidant activity of Phyllanthus species. Ind J Exp Biol. 2004; 42(12): 1212 - 1215.
6. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013; 15(1): 195 - 218.
7. Kapoor S, Saraf S. Role of Curcuma longa in hepatic disorders and nanotechnological approaches to enhance bioavailability. Int J Pharm Sci Res. 2011; 2(4): 120 - 128.
8. Dhiman RK, et al. Hepatoprotective herbal drugs a review. Indian J Exp Biol. 2010; 48(3):71 - 80.
9. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug–herbal interactions. Life Sci. 2006; 78(18): 2131 - 2145.
10. Ghosh N, Ghosh R, Mandal V, Mandal SC. Recent advances in nanotechnology for enhanced therapeutic efficacy of plant extracts in herbal medicine. Curr Pharm Des. 2016;22(29):4350-61.
11. Edenberg HJ. The genetics of alcohol metabolism. Alcohol Res Health. 2007; 30(1): 5 - 13.
12. Seitz HK, Stickel F. Acetaldehyde as an underestimated risk factor for cancer development: role of genetics in ethanol metabolism. Genes Nutr. 2010; 5(2): 121 - 128.
13. Hurley TD, Edenberg HJ. Genes encoding enzymes involved in ethanol metabolism. Alcohol Res. 2012; 34(3): 339 - 344.
14. Das SK, Vasudevan DM. Alcohol-induced oxidative stress. Life Sci. 2007; 81(3): 177 - 187.
15. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med. 2008; 29(1-2): 9 - 16.

16. Bailey SM, Cunningham CC. Contribution of mitochondria to oxidative stress in chronic ethanol consumption. Redox Rep. 2002; 7(4): 197 - 204.
17. Heebøll S, et al. Kupffer cells and the pathogenesis of alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2017; 313(2): G118 - G131.
18. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134(6): 1655 - 1669.
19. Lieber CS. Medical disorders of alcoholism. N Engl J Med. 1995; 333(16): 1058 - 1065.
20. Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015; 148(1): 30 - 36.
21. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 371(9615): 838 - 851.
22. Panossian AG, Wikman G. Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. J Ethnopharmacol. 1999; 29(2): 191 - 221.
23. Asha VV, Pushpangadan P. Hepatoprotective activities of Phyllanthus species. J Ethnopharmacol. 1999; 64(2): 181 - 186.
24. Tripathi DN, Jena GB. Genotoxic and antigenotoxic effects of Phyllanthus amarus in rat liver cells. Food Chem Toxicol. 2010; 48(10): 2721 - 2727.
25. Fiore C, et al. Pharmacological properties of licorice and its components: update. Trends Pharmacol Sci. 2008; 29(10): 548 - 557.
26. Murtaza G, et al. Advances in the role of silymarin in liver diseases. J Clin Gastroenterol. 2014; 48(8): 656 - 663.
27. Abenavoli L, et al. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010; 24(10): 1423 - 1432.
28. Pourmortazavi SM, Hajimirsadeghi SS. Supercritical fluid extraction in plant essential and volatile oil analysis. J Chromatogr A. 2007; 1163(1-2): 2 - 24.
29. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation. J Gen Intern Med. 2008 ;23(6): 854 - 859.
30. Higuchi H, et al. The lack of large-scale RCTs in alcoholic liver disease: call for global collaborations. Am J Gastroenterol. 2010; 105(2): 308 - 309.
31. Girish C, Pradhan SC. Herbal drugs on the liver with special emphasis on Indian herbs. J Clin Exp Hepatol. 2012; 2(2): 144 - 163.
32. Pietta PG. Flavonoids as antioxidants. J Nat Prod. 2000; 63(7): 1035 - 1042.
33. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases. Trends Pharmacol Sci. 2009; 30(2): 85 - 94.
34. Li B, et al. Curcumin exerts anti-fibrotic effects in hepatic fibrosis via TGF-β1/Smad signaling pathway. Mol Biol Rep. 2010; 37(8): 3699 - 3705.
35. Safadi R, Friedman SL. Hepatic fibrosis role of hepatic stellate cell activation. MedGenMed. 2002; 4(3): 27.
36. Jiang C, et al. Gut microbial dysbiosis in the pathogenesis of ALD and potential therapeutic interventions. Microbiology. 2015; 161(Pt 4): 664 - 675.
37. Sharma U, et al. Immunomodulatory effect of Tinospora cordifolia. Indian J Exp Biol. 2012; 50(6): 417-24.
38. Orrego H, et al. Pathogenesis of alcoholic liver disease: overview. Alcohol Alcohol Suppl. 1994; 2: 231 - 243.
39. Kirpich IA, et al. Role of nutrition in alcoholic liver disease. World J Gastroenterol. 2014; 20(28): 8575 - 85.
40. Khoshnam N, et al. Mechanisms linking insulin resistance to hepatic steatosis. Diabetes Metab Syndr Obes. 2021; 14: 1485 - 1500.

41. Shojaee-Moradie F, et al. Exercise training reduces fatty liver and serum triglycerides in obese men. J Clin Endocrinol Metab. 2007; 92(4): 1280 - 1286.
42. Benton T, et al. A role for stress management in reducing alcohol dependence. Curr Psychiatry Rep. 2018; 20(10): 1 - 7.
43. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol. 2005; 100(11): 2583 - 2591.
44. Fu Y, et al. Curcumin in alcoholic liver disease: a preliminary clinical study. J Clin Transl Hepatol. 2015; 3(3): 208 - 211.
45. Panahi Y, et al. Curcuminoids for the management of alcoholic fatty liver disease. Phytother Res. 2015; 29(7): 943 - 948.
46. Singal AK, et al. Pentoxifylline vs. silymarin for severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol. 2009; 104(2): 353 - 360.
47. Dwivedi S, Aggarwal A. A randomised study of polyherbal formulation for the management of alcoholic liver disease. Indian J Tradit Knowl. 2012; 11(3): 459 - 465.
48. Wu JW, et al. Nano-liposomal silymarin: drug release and hepatic targeting studies. Int J Pharm. 2007; 325(1-2): 116 - 123.
49. Abenavoli L, et al. Milk thistle for alcoholic liver disease: a systematic review. J Clin Gastroenterol. 2011; 45(9): 836 - 842.
50. Bruck R, et al. Combining silymarin with antioxidants: a new approach for the treatment of liver damage. Am J Gastroenterol. 2002; 97(9): 2353 - 2357.
51. Zhou H, et al. Nanotechnology applications in liver-targeted drug delivery. J Nanosci Nanotechnol. 2008; 8(2): 533 - 543.
52. Yang B, et al. Controlled release of herbal compounds for liver targeting: a review. J Control Release. 2012; 160(2): 114 - 125.
53. Nicholson JK, et al. The challenges of modeling mammalian biocomplexity. Nat Biotechnol. 2004; 22(10): 1268 - 1274.
54. Zhang L, et al. Machine learning in anti-hepatotoxic drug discovery: a comprehensive approach. Curr Comput Aided Drug Des. 2021; 17(4): 546 - 558.
55. Casino F, et al. Blockchain-based supply chain traceability in herbal medicine: a systematic review. J Med Syst. 2019; 43(7): 246.
56. Calitz C, et al. Access to herbal therapies: bridging cultural acceptance and economic barriers. Health Policy. 2015; 119(3): 367 - 374.
57. Zhou SF, et al. Predicting drug–drug interactions using interaction profiles. Nat Rev Drug Discov. 2008; 7(12): 1010 - 1024.
58. Li B, et al. Curcumin exerts anti-fibrotic effects in hepatic fibrosis via TGF-β1/Smad signaling pathway. Mol Biol Rep. 2010; 37(8): 3699 - 3705.
59. Leung PC, Xue CC, Cheng KF. A comprehensive approach to integrative medicine. Chin J Integr Med. 2010; 16(1): 1 - 3.
60. Yarnall KS, et al. Primary care: Is there enough time for prevention. Am J Public Health. 2003; 93(4): 635 - 641.
61. Thomas L, et al. Fermented herbal products: a new dimension of phytotherapy for chronic diseases. Curr Pharm Des. 2015; 21(31): 4511 - 4518.
62. Sivanandhan G, et al. Genetic engineering of medicinal plants for enhanced production of bioactive compounds. Plant Cell Tissue Organ Cult. 2013; 113(1): 1 - 9.